A KFF Health News investigation published Oct. 13 describes people who say BPC-157 and similar peptide products left them with migraines, eye pain, fatigue, and months of anxiety, nearly three months after an FDA advisory panel voted to ease restrictions on six unapproved peptides and the agency still has not ruled.

The compounds at issue are BPC-157 and TB-500, both widely sold online as research chemicals, along with KPV, MOTS-c, Semax, and epitalon. None is FDA-approved. The panel's recommendation would only let compounding pharmacies use them, which brings oversight of manufacturing but not the safety evidence clinical trials provide.

How the vote actually went

At the Pharmacy Compounding Advisory Committee's July 23 and 24 meeting, BPC-157, KPV, and TB-500 cleared on an 8-6 vote with one abstention. MOTS-c passed 7-5, Semax and epitalon also cleared, and emideltide was the only one rejected, according to AJMC's review of the votes.

That result went against the agency's own scientists, who concluded there was not enough evidence the six peptides improved any condition and flagged possible liver damage and allergic reactions. Concerns raised at the meeting included a 2020 study that found signs of liver toxicity in rats and dogs injected with BPC-157.

What the adverse event reports show

The FDA's database includes a 36-year-old woman hospitalized in December after taking BPC-157 for weight control and a skin condition, and a 48-year-old man hospitalized with what was described as a life-threatening condition after peptide use. These reports are voluntary and unverified, so they cannot prove a peptide caused the harm.

An analysis of millions of health records cited by KFF Health News found more than 1,000 people had told doctors they used BPC-157 since 2020. That analysis has not been peer-reviewed.

The Las Vegas case

The most serious documented incident predates the vote. On July 13, 2025, two women, ages 38 and 51, were injected with peptides at a booth at RAADFest in Las Vegas, left in ambulances, and were intubated. Both have recovered.

Nevada's pharmacy board issued fines in February 2026, ProPublica reported, including $10,000 each for a California-licensed doctor and pharmacist practicing without a Nevada license. Investigators never determined why the women became ill. "We were not able to obtain the product, although attempts were made," said board executive secretary David Wuest.

Bottom line

Brian Lee, a liver specialist at USC who voted no, warned that slow-developing harms might not surface for years. The core uncertainty has not moved: nobody has shown whether these peptides are safe or effective in people, the harm reports cannot establish cause, and the FDA has announced no timeline.